Main Article Content

Gideon Koren


Depression, pregnancy, SSRIs, fluoxetine, fetal alcohol spectrum disorder, misinformation


A summary of the debate regarding the safety of antidepressants in pregnancy is presented through the story of Prozac Baby. This is a diary of a fetus who finds out ( to his horror ) that his mother intends to abort him due to misinformation she has received. The novel, Prozac Baby , was written by Dr . Gideon Koren, based on his experience at Motherisk. An update on the risks of alcohol in pregnancy is also provided.

Abstract 680 | PDF Downloads 224


1. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38(2):90- 96.
2. Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160(5 Pt 1):1190- 1194.
3. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998 [cited 2 014 Jul 12];42(6):1336- 1339. Available from: http://aac.asm.org/cgi/pmidlookup?view=long& pmid=9624471
4. Bar-Oz B, Levichek Z, Moretti ME, et al. Pregnancy outcome following rubella vaccination: a prospective controlled study. Am J Med Genet A 2004;130A(1):52- 54.
5. Trichopoulos D, Zavitsanos X, Koutis C, et al. The victims of Chernobyl in Greece: induced abortions after the accident [letter]. BMJ. 1987 [cited 2014 Jul 8];295(6606):1000. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 1248180
6. Bentur Y, Horlatsch N, Koren G. Exposure to ionizing radiation during pregnancy: perception of teratogenic risk and outcome. Teratology 1991;43(2):109- 112.
7. Cohen- Kerem R, Nulman I, Abramow -Newerly M, et al. Diagnostic radiation in pregnancy: perception versus true risks. J Obstet Gynaecol Can 2006 Jan;28(1):43- 48.
8. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990;41(6):657- 661.
9. Shepard TH, Lemire RJ, ed. Catalog of Teratogenic Agents, 12th ed. Baltimore (MD): Johns Hopkins University Press; 2007.
10. Nul man I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996;53(5):304- 308.
11. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002 [cited 2014 Jul 12];159(11):1889- 1895. Available from: http://ajp.psychiatryonline.org/article.aspx?articl eid=175855 12. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001 [cited 2014 Jul 12];26(1):44- 48. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 1408034/pdf/jpn00089- 0046.pdf
13. Myles N, Newall H, Ward H, et al. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust NZJ Psychiatry 2013;47(11):1002- 1012.
14. Grigoriadis S, Vonder Porten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74(4):e293- e308.
15. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008 [cited 2014 J ul 12];165(5):749- 752. Available from: http://ajp.psychiatryonline.org/article.aspx?articl eid=99899
16. Jimenez -Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2 012 [cited 2014 Jul 13];2(3). pii: e001148. Available from: http://bmjopen.bmj.com/content/2/3/e001148.long
17. Oberlander TF, Misri S, Fitzgerals CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65(2):230- 237.
18. Pogliani L, Schneider L, Dilillo D, et al. Paroxetine and neonatal withdrawal syndrome. BMJ Case Rep 2010 [cited 2014 Jul 13]. pii: bcr1220092528. Available from: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC 3047551
19. Knoppert DC, Nimkar R, Principi T, et al. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit 2006;28(1):5- 7.
20. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ 2005 [cited 2014 Jul 13];172(11):1457- 1459. Available from: http://www.cmaj.ca/conten t/172/11/1457.long
21. Chambers CD, Hernandez -Diaz S, Van Marter LJ, et al. Selective serotonin -reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. NEJM 2006 [cited 2014 Jul 13];354(6):579- 587. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa0 52744
22. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. NEJM 1997 [cited 2014 Jul 13];336(4):258- 262. Available from: http://www.nejm.org/doi/full/10.1056/NEJM199 701233360404
23. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012 [cited 2014 Jul 13];169(11):1165- 1174. Available from: http://ajp.psychiatryonline.org/article.aspx?articl eid=1389519
24. Goodman SH, Rouse MH, Connell AM, et al. Maternal depression and child psychopathology: a meta-analytic review. Clin Child Fam Psychol Rev 2011;14(1):1 -27.
25. Fetal Alcohol Spectrum Disorder (FASD) [Internet]. Ottawa (ON): Public Health Agency of Canada; 2014 Apr 29 [cited 2014 Jul 20]. Available from: http://ww w.phac -aspc.gc.ca/hp - ps/dca -dea/prog -ini/fasd -etcaf/index -eng.php
26. Gareri J, Klein J, Koren G. Drugs of abuse testing in meconium. Clin Chim Acta 2006;366(1- 2):101- 111.
27. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem 2007 [cited 2014 Jul 20];388(7):1455- 1465. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2714867
28. Gray TR, Shakleya DM, Huestis MA. A liquid chromatography tand em mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem 2009 [cited 2014 Jul 20]; 393(8):1977 –1990. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 3165042
29. Bearer CF, Lee S, Salvator AE, et al. Ethyl linoleate in meconium: a biomarker for prenatal ethanol exposure. Alcohol Clin Exp Res 1999;23(3):487- 493. 30. Klein J, Karaskov T, Koren G. Fatty acid ethyl esters: a novel biologic marker for heavy in utero ethanol exposure: a case report. Ther Drug Monit 1999;21(6):644- 646.
31. Bearer CF, Jacobson JL, Jacobson SW, et al. Validation of a new biomarker of fetal exposure to alcohol. J Pediatr 2003;143(4):463- 469.
32. Chan D, Bar -Oz B, Pellerin B, et al. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. Ther Drug Monit 2003;25(3):271- 278.
33. Chan D, Knie B, Boskovic R, et al. Placental handling of fatty acid ethyl esters: perfusion and subcellular studies. J Pharmacol Exp Ther 2004 [cited 2014 Jul 20];310(1):75- 82. Available from: http://jpet.aspetjournals.org/content/31 0/1/75.long
34. Statistics by country for congenital hypothyroidism [Internet]. [place unknown]: Health Grades Inc.; c 2014 [updated 2014 Jun 17; cited 2014 Jul 20]. Available from: http://www.rightdiagnosis.com/c/congenital_hyp othyroidism/stats -country.htm
35. Hanley WB. Newborn screening in Canada – Are we out of step? Paediatr Child Health 2005;10(4):203- 207.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>